Zymenex A/S

Zymenex A/S logo
🇩🇰Denmark
Ownership
Subsidiary
Established
1998-01-01
Employees
11
Market Cap
-
Website
http://www.zymenex.com

Evaluation of Long-term Efficacy of Treatment With Lamazym

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-06-23
Last Posted Date
2020-11-20
Lead Sponsor
Zymenex A/S
Target Recruit Count
18
Registration Number
NCT02478840
Locations
🇩🇰

Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark

A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2012-09-10
Last Posted Date
2020-08-03
Lead Sponsor
Zymenex A/S
Target Recruit Count
25
Registration Number
NCT01681953
Locations
🇩🇰

Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark

🇩🇪

Universitätsmedizin Mainz, Zentrum für Kinder- und Jugendmedizin, Langenbeckstrasse 1, Mainz, Germany

🇫🇷

Hôpital Femme Mère Enfant, Lyon, 59 boulevard Pinel, Bron, France

and more 3 locations

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-09-10
Last Posted Date
2017-03-29
Lead Sponsor
Zymenex A/S
Target Recruit Count
10
Registration Number
NCT01681940
Locations
🇩🇰

Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark

🇧🇪

Kinderneurologie Metabole Ziekten, UZ Brussel, Laarbeeklaan 101, Brussel, Belgium

🇪🇸

Servicio de Pediatría, Hospital Materno Infantil, Reina Sofía, Avda Menéndez Pidal sn, Córdoba, Spain

and more 1 locations

Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Phase 2
Conditions
Interventions
First Posted Date
2011-01-28
Last Posted Date
2012-09-26
Lead Sponsor
Zymenex A/S
Target Recruit Count
10
Registration Number
NCT01285700
Locations
🇩🇰

Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark

Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-12-30
Last Posted Date
2020-08-03
Lead Sponsor
Zymenex A/S
Target Recruit Count
10
Registration Number
NCT01268358

The Natural History of Infantile Globoid Cell Leukodystrophy

First Posted Date
2009-09-24
Last Posted Date
2018-03-08
Lead Sponsor
Zymenex A/S
Target Recruit Count
6
Registration Number
NCT00983879
Locations
🇺🇸

Children's Hospital of Pittsburgh, 4401 One Children's Hospital Drive,4401 Penn Avenue, Pittsburgh, Pennsylvania, United States

The Natural History of Alpha-Mannosidosis

Completed
Conditions
First Posted Date
2007-07-10
Last Posted Date
2020-08-03
Lead Sponsor
Zymenex A/S
Target Recruit Count
45
Registration Number
NCT00498420
Locations
🇩🇪

University of Mainz, Mainz, Germany

🇨🇿

Department of Pediatrics, Charles University, Prague, Czechia

🇳🇴

Department of Medicine, University of Tromsoe, Tromsoe, Norway

and more 1 locations

Porphozym in the Treatment of Acute Attacks in AIP

Phase 2
Completed
Conditions
First Posted Date
2007-01-05
Last Posted Date
2018-03-09
Lead Sponsor
Zymenex A/S
Target Recruit Count
36
Registration Number
NCT00418795
Locations
🇺🇸

Univercity Texas Medical Branch, Galveston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath